Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lowered its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 49.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 152,100 shares of the biopharmaceutical company’s stock after selling 147,900 shares during the period. Vontobel Holding Ltd.’s holdings in Sangamo Therapeutics were worth $155,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in SGMO. Wealth Enhancement Advisory Services LLC increased its position in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 38,850 shares in the last quarter. Golden State Equity Partners increased its position in shares of Sangamo Therapeutics by 35.2% during the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 69,368 shares in the last quarter. Meritage Portfolio Management increased its position in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,740 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after purchasing an additional 57,125 shares in the last quarter. Finally, FMR LLC increased its position in shares of Sangamo Therapeutics by 16.5% during the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock worth $471,000 after purchasing an additional 77,032 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Barclays lifted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Jefferies Financial Group cut their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. Wells Fargo & Company dropped their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 31st. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, January 27th. Finally, Truist Financial dropped their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $5.17.

Sangamo Therapeutics Stock Performance

SGMO opened at $1.07 on Friday. The company’s 50 day simple moving average is $1.45 and its 200 day simple moving average is $1.39. Sangamo Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $3.18. The stock has a market capitalization of $223.26 million, a PE ratio of -1.43 and a beta of 1.30.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.